AP2-18

the iron chelating compound 1,2-diethyl-3-hydroxypyridin-4-one hydrochloride (CP94) was coupled to protoporphyrin IX pro-drug aminolaevulinic acid (ALA) via an ester linkage to produce the iron chelating pharmaceutical compound AP2-18

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Curnow, Alison: 3 articles (03/2022 - 01/2018)
2.	Perry, Alexis: 3 articles (03/2022 - 01/2018)
3.	Wood, Mark: 3 articles (03/2022 - 01/2018)
4.	Magnussen, Anette: 2 articles (03/2022 - 01/2018)
5.	Reburn, Charlotte: 1 article (03/2022)
6.	Anayo, Lizette: 1 article (01/2018)

Related Diseases

1.

Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/01/2022 - "However, 500 µM AP2-18 significantly increased PpIX accumulation and produced a trend of increased cell death within epithelial squamous carcinoma cells. " 03/01/2019 - "No significant dark toxicity was observed in human lung fibroblasts but AP2-18 significantly increased PpIX accumulation above and beyond that achieved with ALA or MAL administration +/- CP94 in both human dermal fibroblasts and epithelial squamous carcinoma cells. " 01/01/2018 - "Human lung fibroblasts (MRC-5) and epithelial squamous carcinoma (A431) cells were treated with PpIX precursors (aminolaevulinic acid [ALA] or methyl-aminolevulinate [MAL]) with or without the separate hydroxypyridinone iron chelating agent (CP94) or alternatively, the new combined iron chelator and PpIX producing agent, AP2-18. "

Related Drugs and Biologics

1.	protoporphyrin IX
2.	1,2-diethyl-3-hydroxypyridin-4-one
3.	Iron
4.	Chelating Agents
5.	Acids